These results indicate that SOS1 is a potentially valuable target for the treatment of both KRAS-mutant cancers and BCR–ABL–positive (BCR–ABL+) CML, thereby necessitating the development of novel strategies to effectively target SOS1. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.